Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 10/20 | 0.33 |
| ▸ | HTR2A | P28223 | 8/20 | 0.33 |
| ▸ | HTR2C | P28335 | 8/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | TERT | O14746 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5037986 | 0.93 | DRD2 (0.34) | HTR7HTR2AHTR2CDRD2 | |
| SCHEMBL6017878 | 0.91 | DRD2 (0.38) | HTR7HTR2AHTR2CDRD2SYK | |
| SCHEMBL6017982 | 0.89 | TPSAB1 (0.32) | MAPT | |
| SCHEMBL6017851 | 0.88 | LMNA (0.39) | MAPT | |
| SCHEMBL6017863 | 0.82 | NPY5R (0.33) | MAPT | |
| SCHEMBL7044189 | 0.81 | ENPP3 (0.33) | MAPT | |
| SCHEMBL6017650 | 0.80 | MCHR1 (0.35) | MAPT | |
| SCHEMBL6017806 | 0.79 | ENPP3 (0.32) | — | |
| SCHEMBL6018066 | 0.79 | ENPP3 (0.31) | — | |
| SCHEMBL5037858 | 0.78 | SMN1; SMN2 (0.42) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041668-B2 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | disclosed |
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | disclosed |
| EP-1432417-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | Aventis Pharma S.A. (FR) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003028721-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | AVENTIS PHARMA S.A. (FR) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | CDKL3, CCNL2, CDKL1 | MAPT 4854/4885HTR7 580/4885HTR2A 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.